AMENDMENT

Kindly amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

IN THE CLAIMS:

Kindly amend the claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

- 1-5. (Cancelled)
- 6. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound of the formula

$$R_1$$
 $N-S-O$ Polycycle R_2 N $N-S-O$

wherein each of R_1 and R_2 is independently selected from H, alkyl, alkenyl, cycloalkyl and aryl; wherein at least one of R_1 and R_2 is H; and

wherein the group Polycycle is a ring system comprising at least four rings, at least two of which are fused;

wherein the compound is an inhibitor of an enzyme having steroid sulphatase activity (E.C.3.1.6.2);

wherein if the sulphamate group on the compound were to be replaced with a sulphate group to form a sulphate compound and incubated with a steroid sulphatase enzyme (E.C.3.1.6.2) at a pH $^{7.4}$ and 37 °C it would provide a K_m value of less than 50 μ M.

7. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound comprising a steroidal ring structure and a sulphamate group of the formula

$$\begin{array}{c|c}
R_1 & O \\
N-S-O \\
R_2 & O
\end{array}$$

wherein each of R_1 and R_2 is independently selected from H, alkyl, alkenyl, cycloalkyl and aryl; wherein at least one of R_1 and R_2 is H; and

wherein the compound is an inhibitor of an enzyme having steroid sulphatase activity (E.C.3.1.6.2);

wherein if the sulphamate group on the compound were to be replaced with a sulphate group to form a sulphate compound and incubated with a steroid sulphatase enzyme (E.C.3.1.6.2) at a pH 7.4 and 37° C it would provide a K_m value of less than $50 \mu M$.

8. (Currently Amended) [A] <u>The pharmaceutical composition of claim 7 comprising a pharmaceutically acceptable carrier or diluent and a compound of the formula</u>

$$\frac{R_1 \setminus O \mid Polycycle}{R_2 \setminus O \mid O}$$

wherein each of R_1 and R_2 is independently selected from H, alkyl, alkenyl, cycloalkyl and aryl; wherein at least one of R_1 and R_2 is H; and

wherein the group Polycycle is a ring system comprising at least three rings, at least two of which are fused;

wherein the compound is an inhibitor of an enzyme having steroid sulphatase activity (E.C.3.1.6.2);

wherein if the sulphamate group on the compound were to be replaced with a sulphate group to form a sulphate compound and incubated with a steroid sulphatase enzyme (E.C.3.1.6.2) at a pH 7.4 and 37°C it would provide a K_m value of less than 50 µM;

wherein the compound is present in an amount to provide 100-500 mg of compound per unit dose.

- 9. (Currently Amended) A <u>The</u> pharmaceutical composition according to claim 6 or 8, wherein the group Polycycle is a ring system comprising at least four rings, at least three of which are fused.
- 10. (Currently Amended) A <u>The pharmaceutical composition according to claim 7</u>, wherein the steroidal ring structure is a residue of a 3-sterol.
- 11. (Currently Amended) A <u>The</u> pharmaceutical composition according to claim 10, wherein the sterol is selected from the group consisting of oestrone, dehydroepiandrosterones, substituted oestrones and substituted dehydroepiandrosterones.
 - 12. (Currently Amended) A <u>The</u> pharmaceutical composition according to any one of

claims 6 to 11 wherein R_1 and R_2 are independently selected from H, or a C_1 - C_{10} alkyl; but wherein at least one of R_1 and R_2 is H.

- 13. (Currently Amended) A <u>The</u> pharmaceutical composition according to any one of claim elaims 6 to 12 wherein R_1 and R_2 are independently selected from H, or C_1 - C_5 alkyl; but wherein at least one of R_1 and R_2 is H.
- 14. (Currently Amended) A The pharmaceutical composition according to any one of claim elaims 6 to 13 wherein R_1 and R_2 are independently selected from H or methyl; but wherein at least one of R_1 and R_2 is H.
- 15. (Currently Amended) A <u>The</u> pharmaceutical composition according to any one of <u>claim</u> claims 6 to 12 wherein R₁ is H and R₂ is H.
- 16. (Currently Amended) A <u>The pharmaceutical composition according to any one of claims 6 to 15 7 or 8</u> wherein the compound is any one of oestrone 3-sulphamate, oestrone-3-N,N-dimethylsulphamate, or oestrone-3-N-monoethylsulphamate.
- 17. (Currently Amended) A <u>The</u> pharmaceutical composition according to claim 6 or 8 wherein the group Polycycle represents the residue of a sterol.
- 18. (Previously Presented) A pharmaceutical composition according to claim 7 wherein the compound is a compound of the formula

wherein the group Polycycle represents the residue of a sterol, and wherein R_1 and R_2 are as defined in claim 7.

- 19. (Previously Presented) A pharmaceutical composition according to claim 17 or 18, wherein the sterol is a 3-sterol.
- 20. (Previously Presented) A pharmaceutical composition according to claim 7 wherein the compound is a compound of the formula

wherein the group Polycycle represents the residue of a 3-sterol, and wherein R₁ and R₂ are H.